We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Intellia Therapeutics Inc (NTLA) USD0.0001

Sell:$89.03 Buy:$93.39 Change: $2.02 (2.26%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: $2.02 (2.26%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Change: $2.02 (2.26%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. The Company's CRISPR/Cas9 is a technology for genome editing, process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To fully realize the transformative potential of CRISPR/Cas9, the Company uses two primary approaches. The Company’s in vivo programs use intravenously administered CRISPR as the therapy, in which its delivery technology enables precise editing of disease-causing genes directly within specific target tissues. The Company’s ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

Contact details

40 Erie St Ste 130
United States
+1 (857) 2856200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$7.29 billion
Shares in issue:
74.34 million
United States
US dollar

Key personnel

  • John Leonard
    President, Chief Executive Officer, Director
  • Glenn Goddard
    Chief Financial Officer, Executive Vice President, Treasurer
  • Laura Sepp-Lorenzino
    Executive Vice President, Chief Scientific Officer
  • James Basta
    Executive Vice President, General Counsel, Corporate Secretary
  • David Lebwohl
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.